About 80% of Asymptomatic People With COVID-19 Develop Symptoms About 80% of Asymptomatic People With COVID-19 Develop Symptoms
A meta-analysis from Switzerland and study from South Korea reach the same estimate — that only about 20% of asymptomatic people with COVID-19 remain so over time.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 28, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi ™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The 2-year results in infants treated with the therapeutic dose of Evrysdi (17/21) showed that they continued to improve and achieve motor milestones. This exploratory analysis showed that an estimated 88% of infants were alive and required no permanent ventilation at two years. In addition, at two years, 59% (10/17 vs. 7/17 at 1-year) of infants were able to sit without support...
Source: Roche Media News - September 28, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi ™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The 2-year results in infants treated with the therapeutic dose of Evrysdi (17/21) showed that they continued to improve and achieve motor milestones. This exploratory analysis showed that an estimated 88% of infants were alive and required no permanent ventilation at two years. In addition, at two years, 59% (10/17 vs. 7/17 at 1-year) of infants were able to sit without support...
Source: Roche Investor Update - September 28, 2020 Category: Pharmaceuticals Source Type: news

Quarantine ordered for 2,500 students at elite Swiss school
Swiss health authorities have ordered a quarantine for 2,500 students at a prestigious hospitality school after “significant outbreaks” of COVID-19 that are suspected to be the byproduct of off-campus partying (Source: ABC News: Health)
Source: ABC News: Health - September 24, 2020 Category: Consumer Health News Tags: Health Source Type: news

ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
LAUSANNE, Switzerland--(BUSINESS WIRE)-- September 24, 2020 -- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 24, 2020 Category: Drugs & Pharmacology Source Type: news

Swiss law would weaken wildlife protection
(Source: ScienceNOW)
Source: ScienceNOW - September 24, 2020 Category: Science Authors: Arlettaz, R., Chapron, G. Tags: letters Source Type: news

Swiss-American CDMO doubles DFW footprint with new Carrollton facility
When Swiss-American CDMO was considering where to grow its manufacturing footprint, the company evaluated locations throughout Texas. In the end, expanding less than a mile from the company's current operations at 2055 Luna Road in Carrollton proved too enticing of an opportunity to pass up. "We decided that the economy of scale and the convenience was something that far outweighed any of the other opportunities," said Komel Gr over, president of the contract development and manufacturing organization.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 23, 2020 Category: Pharmaceuticals Authors: Evan Hoopfer Source Type: news

NeuroRx seeks emergency use authorization for its experimental Covid-19 therapy
NeuroRx said Wednesday it has submitted an emergency use authorization request with the Food and Drug Administration for the company's Covid-19 treatment in patients who have exhausted all approved treatments. NeuroRx is based in Wilmington and has its clinical operations in Radnor. The emergency use authorization would cover the use of RLF-100, which NeuroRx is developing in a partnership with Relief Therapeutic Holdings of Geneva, Switzerland. RLF-100 is a patented formulation of synthetic human… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 23, 2020 Category: Pharmaceuticals Authors: John George Source Type: news

Engineers pre-train AI computers to make them even more powerful
(Swiss Center for Electronics and Microtechnology - CSEM) Engineers at CSEM have developed a new machine-learning method that paves the way for artificial intelligence to be used in applications that until now have been deemed too sensitive. The method, which has been tested by running simulations on a climate-control system for a 100-room building, is poised to deliver energy savings of around 20%. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 22, 2020 Category: Biology Source Type: news

Most people infected with SARS-CoV-2 develop symptoms
(PLOS) While some people who contract SARS-CoV-2 infections never experience any symptoms, there remains disagreement about what proportion of total infections these cases represent. A new study published in the open-access journal PLOS Medicine by Diana Buitrago-Garcia at the University of Bern, Switzerland and colleagues suggests that true asymptomatic cases of SARS-CoV-2 comprise a minority of infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 22, 2020 Category: Infectious Diseases Source Type: news

COVID-19 Can Mimic Acute Stoneless Gallbladder Attack COVID-19 Can Mimic Acute Stoneless Gallbladder Attack
Two case reports from Switzerland show that COVID-19 can mimic acalculous acute cholecystitis and is associated with SARS-CoV-2 in the gallbladder wall.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 21, 2020 Category: Radiology Tags: Infectious Diseases News Source Type: news

First new drug in years reduces recurrence in high risk HR+ early breast cancer
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s 3rd Quarter Sales 2020 Webinar
Roche will publish its Sales Results for the 3rd Quarter of 2020 prior to the opening of the Swiss Stock Exchange on Thursday, October 15th, 2020. (Source: Roche Investor Update)
Source: Roche Investor Update - September 16, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Media News - September 16, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-thr...
Source: Roche Investor Update - September 16, 2020 Category: Pharmaceuticals Source Type: news

Central Europe Largely Avoided the First Coronavirus Wave. Why Are Cases Spiking Now?
Central Europe in the past week has seen a spike in daily confirmed coronavirus cases, a major setback for a region that largely avoided the first wave of the virus in the spring. The Czech Republic, an E.U. member state of 10.7 million, registered a country record of 1,382 new infections on Sep. 11, bringing the country’s total cases to over 32,400. In the last week, nearby countries Hungary, Slovakia and Slovenia have also recorded their highest daily caseloads since the pandemic began. Infections in the Czech Republic previously peaked at around 3 cases per capita (per 100,000 residents) in late March but reached ...
Source: TIME: Health - September 15, 2020 Category: Consumer Health News Authors: Madeline Roache Tags: Uncategorized COVID-19 europe Explainer Londontime Source Type: news

App for MS Aims to Capture Elusive Signals of Progression App for MS Aims to Capture Elusive Signals of Progression
Investigators in Switzerland are testing an application for smartphones that they hope will elucidate subtle signs of disease progression in multiple sclerosis (MS) -- beyond what standard imaging and clinical biomarkers can tell them.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 12, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Featured Review: Education and training for preventing and minimizing workplace aggression directed toward healthcare workers
Do education and training programs reduce aggressive behavior toward healthcare workers?What is aggressive behavior?The International Labour Organization uses the term " workplace violence " defined as " any action, incident or behaviour that departures from reasonable conduct in which a person is threatened, harmed, injured in the course of, or as a direct result of, his or her work " . Experiencing aggressive behavior at work can affect people's ability to do their job well, can cause physical and mental health problems, and can also affect home life. Aggressive behavior may lead to absences from work...
Source: Cochrane News and Events - September 11, 2020 Category: Information Technology Authors: Rachel Klabunde Source Type: news

Tempted to join in or not? Moral temptation and self-reported behaviour in bullying situations - Gutzwiller-Helfenfinger E, Perren S.
We investigate the relationship between adolescents' construction of a transgression relating to a hypothetical temptation and bystander behaviour and bullying (offline and online). A total of 331 Swiss eighth graders completed an electronic questionnaire ... (Source: SafetyLit)
Source: SafetyLit - September 11, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Media News - September 11, 2020 Category: Pharmaceuticals Source Type: news

New data further reinforce Roche ’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
Basel, 11 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analys is from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee...
Source: Roche Investor Update - September 11, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Media News - September 10, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Investor Update - September 10, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Media News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Investor Update - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients
Basel, 8 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) 510k clearance for the cobas ® BKV Test on the cobas® 6800 and 8800 Systems. The test was previously granted FDA Breakthrough Device designation demonstrating the improved treatment or diagnosis of life-threatening diseases or conditions for transplant patients. The test provides standardised, high-quality results that can he lp healthcare professionals better assess the risk of complications caused by the BK virus in transplant patients and identify effective treatment options. BK virus (BKV) is a m...
Source: Roche Investor Update - September 8, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients
Basel, 8 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) 510k clearance for the cobas ® BKV Test on the cobas® 6800 and 8800 Systems. The test was previously granted FDA Breakthrough Device designation demonstrating the improved treatment or diagnosis of life-threatening diseases or conditions for transplant patients. The test provides standardised, high-quality results that can he lp healthcare professionals better assess the risk of complications caused by the BK virus in transplant patients and identify effective treatment options. BK virus (BKV) is a m...
Source: Roche Media News - September 8, 2020 Category: Pharmaceuticals Source Type: news

ICMR reviewing use of tocilizumab for treatment of coronavirus pandemic
Tocilizumab is a rheumatoid arthritis drug manufactured by Swiss pharmaceutical company Roche under the brand name Actemra. The medication is part of the health ministry ’s clinical management protocol for Covid-19 under investigational therapies for patients with moderate symptoms of the illness. (Source: The Economic Times)
Source: The Economic Times - September 8, 2020 Category: Consumer Health News Source Type: news

Intelligent software for district renewable energy management
(Swiss Center for Electronics and Microtechnology - CSEM) CSEM has developed Maestro, an intelligent software application that can manage and schedule the production and use of renewable energies for an entire neighborhood. The system can process a full range of parameters relating to heat pumps, solar panels, rechargeable batteries and electric vehicle charging stations - and generates a real-time strategy to optimize energy costs. Maestro has already been installed in two Swiss homes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 4, 2020 Category: Biology Source Type: news

Curvilinear associations between sexual orientation and problematic substance use, behavioural addictions and mental health among young Swiss men - Wicki M, Marmet S, Studer J, Epaulard O, Gmel G.
BACKGROUND AND AIMS: It is well documented that individuals with a minority sexual orientation face greater risks of problematic substance use (e.g. heavy episodic drinking, alcohol use disorder) and mental health problems. Far less is known about how that... (Source: SafetyLit)
Source: SafetyLit - September 2, 2020 Category: International Medicine & Public Health Tags: Age: Young Adults Source Type: news

Nestle Pays $2 Bln to Secure Aimmune's Allergy Treatment Nestle Pays $2 Bln to Secure Aimmune's Allergy Treatment
Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 1, 2020 Category: Allergy & Immunology Tags: Business of Medicine News Source Type: news

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS
Basel, 1 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas ® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.“Roche is committed to improving diagnostic technologies in the fight against HIV/AIDS,” said Thomas Schinecker, CEO Roche Diagnostics. “Being able to reliably determi...
Source: Roche Investor Update - September 1, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS
Basel, 1 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas ® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.“Roche is committed to improving diagnostic technologies in the fight against HIV/AIDS,” said Thomas Schinecker, CEO Roche Diagnostics. “Being able to reliably determi...
Source: Roche Media News - September 1, 2020 Category: Pharmaceuticals Source Type: news

How dangerous are burning electric cars?
(Swiss Federal Laboratories for Materials Science and Technology (EMPA)) What happens if an electric car burns in a road tunnel or an underground car park? In the Hagerbach test tunnel in Switzerland, Empa researchers and tunnel safety expert Lars Derek Mellert set fire to battery cells of electric cars, analyzed the distribution of soot and smoke gases and the chemical residues in the extinguishing water. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2020 Category: International Medicine & Public Health Source Type: news

Factors associated with going outdoors frequently: a cross-sectional study among Swiss community-dwelling older adults - Spaltenstein J, B üla C, Santos-Eggimann B, Krief H, Seematter-Bagnoud L.
This study examines potential risk and protective factors associated with going outdoors frequently among older persons, and whether these factors vary according to physical limitations. DESIGN: Cross-sectional analysis. SETTING AND PART... (Source: SafetyLit)
Source: SafetyLit - August 31, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - August 28, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Media News - August 28, 2020 Category: Pharmaceuticals Source Type: news

UK coronavirus live: daily cases jump to 1,522; Switzerland, Czech Republic and Jamaica added to quarantine list
UK ’s daily cases tallyup from 1,048 on Wednesday; transport secretary confirmsthree countries added to quarantine list; government falls short of contact-tracing targetfor ninth week in rowData on care home deaths kept secret ‘to protect commercial interests’£13 a day to self-isolate ‘slap in face’ for low-paidFootballer Pogba tests positiveHundreds self-isolate amid Norfolk poultry plant outbreakGlobal coronavirus latest - live6.51pmBSTHere ’s a round-up of the key events of the day.•The government announced the biggest single-day increase in coronavirus cases since 12 June ...
Source: Guardian Unlimited Science - August 27, 2020 Category: Science Authors: Archie Bland (now); Caroline Davies and Damien Gayle (earlier) Tags: Coronavirus outbreak Politics UK news Boris Johnson Matt Hancock Infectious diseases Science Source Type: news

Swiss explore renewal of ‘secret deal’ with China, which allows officials from Beijing to enter the country and question Chinese...
Swiss authorities want to renew a discreet agreement allowing Beijing officials to enter the country and question Chinese citizens... (Source: Reuters: Health)
Source: Reuters: Health - August 26, 2020 Category: Consumer Health News Source Type: news

Verily launches new health insurance venture
Dubbed Coefficient Insurance Company, it will combine Verily and Swiss Re Corporate Solutions'technology.   (Source: mobihealthnews)
Source: mobihealthnews - August 25, 2020 Category: Information Technology Source Type: news

Physicians' views on the usefulness of practical tools for assessing the driving ability of older drivers: a cross-sectional study - Sebo P.
OBJECTIVE: We aimed to explore Swiss physicians' views on the usefulness of a self-administered questionnaire completed by older drivers before the consultation and a reference guide summarising current Swiss guidelines on the fitness-to-drive assessment o... (Source: SafetyLit)
Source: SafetyLit - August 24, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

France sees another sharp rise in coronavirus cases with 4,700 new infections - up 1,000 in a day
There have also been spikes in Spain, Germany, Austria, Switzerland and Croatia - much of it blamed on holidaying Europeans and youngsters enjoying parties in the summer heatwave. (Source: the Mail online | Health)
Source: the Mail online | Health - August 21, 2020 Category: Consumer Health News Source Type: news

Despite Big Pharma objection, dethroned unicorn Proteus sold in bankruptcy court for $15M
Once valued at $1.5 billion based on the promise of embedding a variety of drugs with sensors to help doctors determine if patients actually were taking prescribed medicines, Proteus Digital Health Inc. was sold out of U.S. Bankruptcy Court to a unit of onetime partner Otsuka Pharmaceuticals Inc. for $15 million. The sale, just two months after Redwood City-based Proteus filed for Chapter 11 bankruptcy protection, was fought to the end by a group of investors, including Swiss drug giant Novartis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Despite Big Pharma objection, dethroned unicorn Proteus sold in bankruptcy court for $15M
Once valued at $1.5 billion based on the promise of embedding a variety of drugs with sensors to help doctors determine if patients actually were taking prescribed medicines, Proteus Digital Health Inc. was sold out of U.S. Bankruptcy Court to a unit of onetime partner Otsuka Pharmaceuticals Inc. for $15 million. The sale, just two months after Redwood City-based Proteus filed for Chapter 11 bankruptcy protection, was fought to the end by a group of investors, including Swiss drug giant Novartis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 20, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Regeneron teams up with Swiss drugmaker to boost production of Covid-19 treatment
Regeneron Pharmaceuticals would nearly quadruple production capacity of its Covid-19 antibody cocktail under a new agreement with Swiss drug maker Roche. "This major collaboration with Roche provides important scale and global expertise to bring REGN-COV2 to many more patients," said Regeneron president and chief executive Len Schleifer. Under the terms of the agreement, Regeneron would focus on manufacturing and sales of the cocktail in the Unite d States and Roche would be responsible for distribution… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2020 Category: Biotechnology Authors: Robin K. Cooper Source Type: news

Aerogel - the micro structural material of the future
(Swiss Federal Laboratories for Materials Science and Technology (EMPA)) Aerogel is an excellent thermal insulator. So far, however, it has mainly been used on a large scale, for example in environmental technology, in physical experiments or in industrial catalysis. Empa researchers have now succeeded in making aerogels accessible to microelectronics and precision engineering: An article in the latest issue of the scientific journal " Nature " shows how 3D-printed parts made of silica aerogels and silica composite materials can be manufactured with high precision. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 20, 2020 Category: Biology Source Type: news

👉 Swiss town coated in CHOCOLATE after ventilation mishap at Lindt factory via Hvper.com
(Source: Reuters: Health)
Source: Reuters: Health - August 19, 2020 Category: Consumer Health News Source Type: news

Naturally occurring antibodies against prion proteins found in humans
(EMBO) Antibodies targeting the normal PrP version of the prion protein have been found in humans selected at random with no history of any associated transmissible spongiform encephalopathies. In EMBO Molecular Medicine, researchers at the University of Zurich and Novartis Institutes for BioMedical Research in Switzerland report on active antibodies against PrP at high levels in a small proportion of individuals, 21 of 37,894 hospital patients screened for presence of anti-PrP IgGs, the most common form of immunoglobulin. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 17, 2020 Category: Biology Source Type: news